A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
This Phase 1 clinical trial is looking at an experimental drug named CTIM-76. It is designed for adults with advanced solid tumours, particularly ovarian cancer that has come back, as well as testicular and endometrial (womb) cancers. Because this is a Phase 1 study, it is the first time CTIM-76 is being tested in humans. Doctors want to understand how safe the treatment is, what side effects it might cause, and how it behaves inside the body. They also want to find the safest and most effective dose for future studies. Taking part involves having the new treatment, regular hospital appointments, blood tests, and health scans so the study team can monitor your wellbeing closely. This trial may offer an option for people whose cancer has not responded to standard treatments.
At a glance
What is this study about?
When cancer returns after treatment, or spreads to other parts of the body, standard options like surgery or standard chemotherapy can sometimes stop working. This trial is studying a new experimental medicine called CTIM-76 to see if it could become a helpful future treatment for advanced solid tumours, including ovarian, testicular, and endometrial (womb) cancer.
Because this is a Phase 1 trial, it is the very first time this drug is being given to people. Researchers carry out Phase 1 studies in small groups of volunteers. Their main priority is finding out how safe the medicine is, discovering the right dose to use, and learning about any side effects it might cause.
Taking part in early research like this helps scientists discover new ways to fight cancer. While it is too early to know if CTIM-76 will shrink tumours or slow cancer growth, the knowledge gained from this study will help doctors design future treatments for people facing similar conditions.
Key takeaways
- Tests a new medicine, CTIM-76, for the first time in humans.
- Open to adults with advanced solid tumours, including ovarian, testicular, and womb cancers.
- The primary aim is to check the drug's safety and find the best dose.
- Requires frequent hospital visits, regular scans, and detailed health checks.
- Participation is entirely voluntary, and you can stop at any time.
Who may be eligible?
This trial is open to adults aged 18 and over who have an advanced solid tumour that has returned or spread. It specifically focuses on recurring ovarian cancer, testicular cancer, and endometrial (womb) cancer, especially where standard treatments are no longer working.
To be considered, you will generally need to be well enough to carry out daily activities and have adequate liver, kidney, and bone marrow function. Your hospital team will check your recent medical history to make sure taking part is safe for you.
You may not be eligible if you have other serious medical conditions, such as severe heart disease or an active, uncontrolled infection. Women who are pregnant or breastfeeding, and people who have recently had certain other cancer treatments, are also usually unable to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with an advanced solid tumour, such as ovarian, testicular, or womb cancer.
- My cancer has returned or progressed despite previous treatments.
- I am well enough to attend frequent hospital visits for tests and monitoring.
- I am not currently pregnant or breastfeeding.
What does participation involve?
If you decide to join this study, you will receive the study drug CTIM-76 under the supervision of a specialist hospital team. You will have regular clinic visits where doctors will check your vital signs, take blood and urine samples, and carry out imaging scans (such as CT or MRI scans) to see how your tumour responds. Because this is an early safety study, you will be monitored very closely, which may mean spending several hours at the hospital on treatment days. The total duration of the study depends on how well you tolerate the drug and whether it helps manage your cancer. Even after you finish taking the drug, the team will follow up with you through clinic visits or phone calls to monitor your long-term health.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedSpain
Common questions
What does 'Phase 1' mean?
A Phase 1 trial is the earliest stage of human testing. It focuses mainly on finding out if a new drug is safe, what side effects it causes, and the best dose to give.
Do I have to pay to take part in this trial?
No. The study drug and all trial-related tests are provided free of charge, and some trials can help cover your travel expenses.
Can I leave the study if I change my mind?
Yes. You have the right to withdraw from the study at any time, for any reason, without giving an explanation and without losing your standard medical care.
Will this drug cure my cancer?
Because this is an early safety trial, doctors cannot promise that the drug will shrink your tumour or cure your cancer, though they will monitor its effects closely.
Can I carry on with my normal daily activities?
Many people continue their routine, but you may feel tired or need to spend more time at hospital appointments. Your trial doctor can advise you based on how you feel.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.